<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1FFD79A0-0681-4141-A504-FDE130EF7F33"><gtr:id>1FFD79A0-0681-4141-A504-FDE130EF7F33</gtr:id><gtr:firstName>Mahesh</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F3"><gtr:id>A7C85A53-D9BD-4BA4-A254-44F26518DC24</gtr:id><gtr:title>Clinical Trials in Colorectal Cancer.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/3</gtr:grantReference><gtr:abstractText>The MRC-CTU colorectal team co-ordinate large controlled clinical trials aimed at progressively improving treatment outcomes in advanced colorectal cancer and early rectal cancer.||Four trials have tested chemotherapy and biological therapies in patients with advanced colorectal cancers. These are quite frequent tumours, but there have been major improvements, chemotherapy having increased survival from about 6 months to 10-12 months, and to between 16 20 months with addition of new agents. The COIN trial explores the addition of newer selective biological therapies hoping to further improve patients chances of living longer. COIN also tests the effectiveness of intermittent combination chemotherapy (giving patients holidays off chemotherapy). The COIN-B trial will provide further information on safety and effectiveness of adding biologics to intermittent chemotherapy. FOCUS3 is an initial test of molecular treatment selection based on characteristics of individual patients tumours. This is potentially a critical step in individualising therapy, selecting best options for each person and minimising use of agents that are unlikely to benefit him/her.||The team have also completed an important trial in early rectal cancer, which are likely to change the way patients with rectal cancer are treated both in the UK and worldwide by showing that the addition of a short course of radiotherapy prior to surgery results in a reduction in the likelihood of a rectal cancer returning.</gtr:abstractText><gtr:technicalSummary>Colorectal cancer is the second most common site of cancer, with around 1 million cases diagnosed each year worldwide, accounting for about 9% of all new cancer cases. In the UK around 35,000 people are diagnosed with the disease, and 16,000 patients die each year (CR-UK Cancer Stats 2003). Most patients die of advanced disease.||The colorectal team continues to run a series of large multicentre randomised trials, mainly aimed at optimising the treatment of patients with advanced disease. The team also manage follow-up of a trial in rectal cancer which completed accrual in 2005.||FOCUS (CR08) commenced in May 2000 and recruited 2,135 patients by December 2003. The trial was a 5-arm randomised trial comparing the use of irinotecan and oxaliplatin in combination with 5FU either given as first-line treatment or held in reserve as second-line treatment after the failure of 5FU alone. The control arm was the UK standard treatment of 5FU followed on progression by single-agent irinotecan. All four of the research arms gave longer overall survival than the control arm. Most of the differences did not reach the predetermined 1% significance level for superiority, the comparison between the first-line combination of Irinotecan and 5FU and the control arm was the most promising (HR 0.84 (0.73-0.96; p=0.01)). The main results from the trial were published in the Lancet in 2007 (Seymour et al., Lancet 2007; 370:143-152.).||Furthermore, all patients in FOCUS were asked at the time of randomisation for consent to retrieve surplus stored pathology material for molecular study. Thus FOCUS provided an excellent resource for studying the relationship between molecular variables and treatment effect. Preliminary results were presented at the American Society of Clinical Oncology (ASCO) annual meetings in 2004 and 2006. Several papers on this work have been published, while another was recently submitted for publication. This tumour tissue resource has been further expanded in the sequence of trials that followed and represents an increasingly valuable asset for biomarker and translational research.||FOCUS2 (CR09) opened in January 2004 and closed in July 2006 following the recruitment of 459 patients. FOCUS2 was designed to assess lower-dose treatment for patients with advanced colorectal cancer who were ineligible or unsuitable for trials of full-dose combination chemotherapy because of poor general health status, advanced age or both. Patients were randomised in a 2x2 fashion to receive one of the four following chemotherapy treatment plans:||1st-line: 5FU/FA (MdG) 1st-line: capecitabine (Cap)|2nd-line: Oxaliplatin(Ox)MdG 2nd-line: OxMdG|1st-line: OxMdG 1st-line: OxCap||Chemotherapy was started at 80% of standard dose with the option of increasing to 100% at 6 weeks if well-tolerated. The principal outcome measures were progression free survival for the addition of oxaliplatin (Ox) comparison and quality of life for the MdG/Capecitabine (Cap) comparison. Preliminary results have been presented in the form of a poster presentation at ASCO 2007 and the National Cancer Research Institute (NCRI) meeting in 2007. An oral presentation was given at the European CanCer Organisation (ECCO) meeting in 2007. Ox containing regimens showed a slightly longer progression free survival (PFS) however, these differences did not reach the pre-defined significance level of 5%. The addition of Ox did show an improvement in patients reported quality of life (QL) at 12 weeks (62% vs. 49%, p=0.04). There was no impact on the overall survival (OS) despite the significantly improved response rates (15% vs. 41%, p&amp;lt;0.001). There was some evidence that the addition of oxaliplatin reduced the ability to dose increase at the 6 week time point despite there being no difference in the grade 33 toxicity rates. The substitution of MdG with Cap had no effect on PFS, OS or the QL at 12 weeks, however there was a statistically significant increase in overall grade 33 toxicity (2</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1078000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B0C974F5-9F90-438E-8FAA-1B2BAAF0B06A</gtr:id><gtr:title>Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c39e0c16568e5af0ec6d35554a48ac0d"><gtr:id>c39e0c16568e5af0ec6d35554a48ac0d</gtr:id><gtr:otherNames>Lieu CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>5aa8fd6b81b6f5.25565408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AFC5D96-5037-410B-A51B-771DB5421A46</gtr:id><gtr:title>Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2-3 randomised trial</gtr:title><gtr:parentPublicationTitle>The Lancet Gastroenterology &amp; Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8fc7aab55825204e4ea4a91d8c76fa9"><gtr:id>f8fc7aab55825204e4ea4a91d8c76fa9</gtr:id><gtr:otherNames>Adams R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a999e37241945.08840660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAB1EB71-3F74-49AB-87A7-F8FA86884665</gtr:id><gtr:title>Changing the Paradigm-Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.</gtr:title><gtr:parentPublicationTitle>The oncologist</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6102ec8bfcb4cfb87cb034e8c4067870"><gtr:id>6102ec8bfcb4cfb87cb034e8c4067870</gtr:id><gtr:otherNames>Lawler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1083-7159</gtr:issn><gtr:outcomeId>56c49d70e64848.76086201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7E63670-41AC-4AC7-BC20-C70E29557A06</gtr:id><gtr:title>Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc8d4669ee974944842d57b63d047f75"><gtr:id>cc8d4669ee974944842d57b63d047f75</gtr:id><gtr:otherNames>Phipps AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>56c49efc944933.04740717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F0293E8-81BB-4539-967D-DA303006BE67</gtr:id><gtr:title>Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_15667_27_23585368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4003A7A-AF5A-44F1-B118-282276BC5598</gtr:id><gtr:title>Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/967b878cddb0708dbfb2fe7be3830f4e"><gtr:id>967b878cddb0708dbfb2fe7be3830f4e</gtr:id><gtr:otherNames>Jarvis D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b98dd7b21a21.61813176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E55C0F4-A296-47AA-A15D-407A579F45C6</gtr:id><gtr:title>Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb7b6926531d2216e86891660ee26e15"><gtr:id>bb7b6926531d2216e86891660ee26e15</gtr:id><gtr:otherNames>Madi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>5a9aa9159349f3.59997146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B58A62AE-303D-4D73-9767-6F299E8DBE93</gtr:id><gtr:title>A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e96a47f840e64fa213f5d842daf1e753"><gtr:id>e96a47f840e64fa213f5d842daf1e753</gtr:id><gtr:otherNames>Maughan TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5461fc538e9415.93615826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64F4EDF7-FB61-4350-8E4D-9B5759A27ADA</gtr:id><gtr:title>Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56c49d7014a836.90720651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C429B96C-8FDC-47B2-985B-6FB835B8DAD6</gtr:id><gtr:title>Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11b60f660066e306ba7823f7c9fe1777"><gtr:id>11b60f660066e306ba7823f7c9fe1777</gtr:id><gtr:otherNames>Venderbosch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56c49d6fd11961.59332839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0D89FB1-3945-4981-A611-6E5E72144FB8</gtr:id><gtr:title>Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d84e14633aa9ff4625fa58200b2b9a27"><gtr:id>d84e14633aa9ff4625fa58200b2b9a27</gtr:id><gtr:otherNames>Tanskanen T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>5a99a0a65e6410.23037003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F413EE98-F9E5-4CDB-9DEC-E24204628565</gtr:id><gtr:title>Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d18f86bb840d3de500000b0dfb8b07da"><gtr:id>d18f86bb840d3de500000b0dfb8b07da</gtr:id><gtr:otherNames>Orlando G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>58b98fb8000ef8.76399205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3466E1A2-0B9B-4698-AEC2-EC40FC4D5339</gtr:id><gtr:title>Evaluating many treatments and biomarkers in oncology: a new design.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723c80601d0630665bb715ff60df02b8"><gtr:id>723c80601d0630665bb715ff60df02b8</gtr:id><gtr:otherNames>Kaplan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>XRLhmKwv2rf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>739B083A-6429-44E4-BD59-388F2ACCBE65</gtr:id><gtr:title>Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy &amp;plusmn; cetuximab.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_15667_27_23741067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84F4CA47-B9B7-468D-8A1D-F4B66AD22180</gtr:id><gtr:title>Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/507b8703d4ee1882ae5ae89581f7ef19"><gtr:id>507b8703d4ee1882ae5ae89581f7ef19</gtr:id><gtr:otherNames>Rodriguez-Broadbent H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>5a99a0a6995be3.24027038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D864FB64-5B8C-4AEC-AA30-20B55B303CF9</gtr:id><gtr:title>Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbe30c8eb6a4737672e1453b53d2be21"><gtr:id>dbe30c8eb6a4737672e1453b53d2be21</gtr:id><gtr:otherNames>Grenader T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b99006d3eea1.59096385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D5FBBF1-3899-4486-8D6C-19664B8A1F07</gtr:id><gtr:title>Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd1ec81851500ff77017b336a8cf7b5"><gtr:id>acd1ec81851500ff77017b336a8cf7b5</gtr:id><gtr:otherNames>Wasan H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>545b8912a20a32.29090280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>584BC85A-ACF7-4846-9E85-79F45301BD11</gtr:id><gtr:title>Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>pm_15667_27_23852950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18712752-7AD7-4A79-ABC6-22F173E3ED41</gtr:id><gtr:title>Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.</gtr:title><gtr:parentPublicationTitle>Anti-cancer drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7df0bc168653e30ae5dbe3eedd03ffae"><gtr:id>7df0bc168653e30ae5dbe3eedd03ffae</gtr:id><gtr:otherNames>Wood G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-4973</gtr:issn><gtr:outcomeId>5a99a0a6c79990.41245541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDDCA5EC-CA0E-450A-A0DE-44EB05F03630</gtr:id><gtr:title>High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/968bb38ba508b0d86999082d4c518998"><gtr:id>968bb38ba508b0d86999082d4c518998</gtr:id><gtr:otherNames>Downing A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5a9aa99ec36d57.25014037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2BE39F7-9EC4-4F7D-979A-2233894070E6</gtr:id><gtr:title>A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08de9b7f92a6e1bce87ca67f1f46e310"><gtr:id>08de9b7f92a6e1bce87ca67f1f46e310</gtr:id><gtr:otherNames>Al-Tassan NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56c49efcb99146.28706828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CFC27A7-96FF-42AD-8924-5935A742729D</gtr:id><gtr:title>andLocus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/937f68dcff8d968aaae259fa88742113"><gtr:id>937f68dcff8d968aaae259fa88742113</gtr:id><gtr:otherNames>Summers MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>58b98d0c7cdfe1.75925212</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/3</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>